BMI View: Non-governmental organisations will continue to expand healthcare access in Myanmar - a
boon for the country's pharmaceutical market. However, the country's poor protection of intellectual
property, a weak healthcare system and political instability continues to pose ..."
BMI View: The considerable increase in government health expenditure in 2012 highlights Myanmar's
commitment to improving healthcare. However, there are several barriers to the improvement of medical
services, such as limited funding for healthcare, a lack of basic re ..."
BMI View: Commercial opportunities in Myanmar's healthcare sector are largely derived from its large
unmet medical needs and underinvestment. However, we maintain that significant improvements are
required if Myanmar is to realise its ambitious public health insurance ..."
BMI View: Despite strong growth potential, Myanmar remains as one of the least attractive country in Asia
Pacific due to its small market size and general low spending on healthcare and pharmaceuticals. We
expect investors to turn to Myanmar only when the country has ..."
BMI View: We maintain that the growth potential of Mynamar's pharmaceutical market can only be achieved over the long term as it is necessary for the country to improve on its basic infrastructure, which is required for the industry. In addition, due to its small market size, we ..."
BMI View: Despite its small size, Myanmar's pharmaceutical market offers drugmakers strong revenueearning
opportunities. Generic and over-the-counter drug companies in particular stand to benefit, as the
population's per capita expenditure on pharmaceuticals and healthcare rema ..."